IPO Databook: Dizal Pharmaceutical (HK) - Aug 2026

98 Views29 Aug 2026 10:09

SUMMARY

Dizal Pharmaceutical is a commercial-stage biopharmaceutical company focused on oncology and hematological diseases, with two commercialized products and a pipeline.
ZEGFROVY® is the world's first small molecule EGFR TKI approved for lung cancer with EGFR exon20ins mutations.
Revenue was RMB801,136 thousand in 2025 and RMB522,693 thousand for the six months ended June 30, 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream